#begin document (wsj_2382_0); part 000
wsj_2382	0	0	Food	NNP	(TOP(S(NP(NML(NML(NML*	-	-	-	-	(3|(6
wsj_2382	0	1	and	CC	*	-	-	-	-	-
wsj_2382	0	2	Drug	NNP	*)	-	-	-	-	-
wsj_2382	0	3	Administration	NNP	*)	-	-	-	-	3)
wsj_2382	0	4	spokesman	NN	*)	-	-	-	-	-
wsj_2382	0	5	Jeff	NNP	*	-	-	-	-	-
wsj_2382	0	6	Nesbit	NNP	*)	-	-	-	-	6)
wsj_2382	0	7	said	VBD	(VP*	say	01	1	-	-
wsj_2382	0	8	the	DT	(SBAR(S(NP*	-	-	-	-	(3
wsj_2382	0	9	agency	NN	*)	agency	-	1	-	3)
wsj_2382	0	10	has	VBZ	(VP*	-	-	-	-	-
wsj_2382	0	11	turned	VBN	(VP*	turn	12	11	-	-
wsj_2382	0	12	over	RP	(PRT*)	-	-	-	-	-
wsj_2382	0	13	evidence	NN	(NP*)	evidence	-	3	-	-
wsj_2382	0	14	in	IN	(PP*	-	-	-	-	-
wsj_2382	0	15	a	DT	(NP(NP*	-	-	-	-	-
wsj_2382	0	16	criminal	JJ	*	-	-	-	-	-
wsj_2382	0	17	investigation	NN	*)	investigation	-	1	-	-
wsj_2382	0	18	concerning	VBG	(VP*	concern	02	1	-	-
wsj_2382	0	19	Vitarine	NNP	(NP*	-	-	-	-	(0
wsj_2382	0	20	Pharmaceuticals	NNP	*	-	-	-	-	-
wsj_2382	0	21	Inc.	NNP	*))))	-	-	-	-	0)
wsj_2382	0	22	to	IN	(PP*	-	-	-	-	-
wsj_2382	0	23	the	DT	(NP(NP(NP*	-	-	-	-	-
wsj_2382	0	24	U.S.	NNP	*	-	-	-	-	-
wsj_2382	0	25	Attorney	NNP	*	-	-	-	-	-
wsj_2382	0	26	's	POS	*)	-	-	-	-	-
wsj_2382	0	27	office	NN	*)	office	-	5	-	-
wsj_2382	0	28	in	IN	(PP*	-	-	-	-	-
wsj_2382	0	29	Baltimore	NNP	(NP*)))))))))	-	-	-	-	-
wsj_2382	0	30	.	.	*))	-	-	-	-	-

wsj_2382	0	0	Neither	DT	(TOP(S(NP*	-	-	-	-	-
wsj_2382	0	1	Vitarine	NNP	(NP*)	-	-	-	-	(0)
wsj_2382	0	2	nor	CC	*	-	-	-	-	-
wsj_2382	0	3	any	DT	(NP(NP*)	-	-	-	-	-
wsj_2382	0	4	of	IN	(PP*	-	-	-	-	-
wsj_2382	0	5	the	DT	(NP(NP*	-	-	-	-	(3
wsj_2382	0	6	Springfield	NNP	(NML(NML*	-	-	-	-	-
wsj_2382	0	7	Gardens	NNP	*)	-	-	-	-	-
wsj_2382	0	8	,	,	*	-	-	-	-	-
wsj_2382	0	9	N.Y.	NNP	(NML*)	-	-	-	-	-
wsj_2382	0	10	,	,	*)	-	-	-	-	-
wsj_2382	0	11	company	NN	*	company	-	1	-	-
wsj_2382	0	12	's	POS	*)	-	-	-	-	3)
wsj_2382	0	13	officials	NNS	*	official	-	1	-	-
wsj_2382	0	14	or	CC	*	-	-	-	-	-
wsj_2382	0	15	employees	NNS	*))))	-	-	-	-	-
wsj_2382	0	16	have	VBP	(VP*	-	-	-	-	-
wsj_2382	0	17	been	VBN	(VP*	-	-	-	-	-
wsj_2382	0	18	charged	VBN	(VP*	charge	05	3	-	-
wsj_2382	0	19	with	IN	(PP*	-	-	-	-	-
wsj_2382	0	20	any	DT	(NP*	-	-	-	-	-
wsj_2382	0	21	crimes	NNS	*)))))	crime	-	1	-	-
wsj_2382	0	22	.	.	*))	-	-	-	-	-

wsj_2382	0	0	Vitarine	NNP	(TOP(S(NP*)	-	-	-	-	(0)
wsj_2382	0	1	won	VBD	(VP(VP*	win	01	2	-	-
wsj_2382	0	2	approval	NN	(NP*	approval	01	1	-	-
wsj_2382	0	3	to	TO	(S(VP*	-	-	-	-	-
wsj_2382	0	4	market	VB	(VP*	market	01	1	-	-
wsj_2382	0	5	a	DT	(NP(NP*	-	-	-	-	-
wsj_2382	0	6	version	NN	*)	version	-	2	-	-
wsj_2382	0	7	of	IN	(PP*	-	-	-	-	-
wsj_2382	0	8	a	DT	(NP*	-	-	-	-	-
wsj_2382	0	9	blood	NN	(NML*	-	-	-	-	-
wsj_2382	0	10	pressure	NN	*)	pressure	-	1	-	-
wsj_2382	0	11	medicine	NN	*))))))))	medicine	-	1	-	-
wsj_2382	0	12	but	CC	*	-	-	-	-	-
wsj_2382	0	13	acknowledged	VBD	(VP*	acknowledge	01	1	-	-
wsj_2382	0	14	that	IN	(SBAR*	-	-	-	-	-
wsj_2382	0	15	it	PRP	(S(NP*)	-	-	-	-	(0)
wsj_2382	0	16	substituted	VBD	(VP*	substitute	01	1	-	-
wsj_2382	0	17	a	DT	(NP(NP*	-	-	-	-	(2
wsj_2382	0	18	SmithKline	NNP	(NML*	-	-	-	-	-
wsj_2382	0	19	Beecham	NNP	*	-	-	-	-	-
wsj_2382	0	20	PLC	NNP	*)	-	-	-	-	-
wsj_2382	0	21	product	NN	*))	product	-	1	-	2)
wsj_2382	0	22	as	IN	(PP*	-	-	-	-	-
wsj_2382	0	23	its	PRP$	(NP*	-	-	-	-	(4|(0)
wsj_2382	0	24	own	JJ	*))	-	-	-	-	4)
wsj_2382	0	25	in	IN	(PP*	-	-	-	-	-
wsj_2382	0	26	tests	NNS	(NP*)))))))	test	-	1	-	(7)
wsj_2382	0	27	.	.	*))	-	-	-	-	-

wsj_2382	0	0	Mr.	NNP	(TOP(S(NP*	-	-	-	-	(6
wsj_2382	0	1	Nesbit	NNP	*)	-	-	-	-	6)
wsj_2382	0	2	also	RB	(ADVP*)	-	-	-	-	-
wsj_2382	0	3	said	VBD	(VP*	say	01	1	-	-
wsj_2382	0	4	the	DT	(SBAR(S(NP*	-	-	-	-	(3
wsj_2382	0	5	FDA	NNP	*)	-	-	-	-	3)
wsj_2382	0	6	has	VBZ	(VP*	-	-	-	-	-
wsj_2382	0	7	asked	VBN	(VP*	ask	02	2	-	-
wsj_2382	0	8	Bolar	NNP	(NP*	-	-	-	-	(1
wsj_2382	0	9	Pharmaceutical	NNP	*	-	-	-	-	-
wsj_2382	0	10	Co.	NNP	*)	-	-	-	-	1)
wsj_2382	0	11	to	TO	(S(VP*	-	-	-	-	-
wsj_2382	0	12	recall	VB	(VP*	recall	01	2	-	(8)
wsj_2382	0	13	at	IN	(PP*	-	-	-	-	-
wsj_2382	0	14	the	DT	(NP*	-	-	-	-	-
wsj_2382	0	15	retail	JJ	*	-	-	-	-	-
wsj_2382	0	16	level	NN	*))	level	-	2	-	-
wsj_2382	0	17	its	PRP$	(NP*	-	-	-	-	(4|(1)
wsj_2382	0	18	urinary	JJ	(NML*	-	-	-	-	-
wsj_2382	0	19	tract	NN	*)	tract	-	2	-	-
wsj_2382	0	20	antibiotic	NN	*)))))))))	-	-	-	-	4)
wsj_2382	0	21	.	.	*))	-	-	-	-	-

wsj_2382	0	0	But	CC	(TOP(S(S*	-	-	-	-	-
wsj_2382	0	1	so	RB	(ADVP*	-	-	-	-	-
wsj_2382	0	2	far	RB	*)	-	-	-	-	-
wsj_2382	0	3	the	DT	(NP*	-	-	-	-	(1
wsj_2382	0	4	company	NN	*)	company	-	1	-	1)
wsj_2382	0	5	has	VBZ	(VP*	-	-	-	-	-
wsj_2382	0	6	n't	RB	*	-	-	-	-	-
wsj_2382	0	7	complied	VBN	(VP*	comply	01	1	-	-
wsj_2382	0	8	with	IN	(PP*	-	-	-	-	-
wsj_2382	0	9	that	DT	(NP*	-	-	-	-	(8
wsj_2382	0	10	request	NN	*)))))	request	01	1	-	8)
wsj_2382	0	11	,	,	*	-	-	-	-	-
wsj_2382	0	12	the	DT	(NP*	-	-	-	-	(6
wsj_2382	0	13	spokesman	NN	*)	-	-	-	-	6)
wsj_2382	0	14	said	VBD	(VP*)	say	01	1	-	-
wsj_2382	0	15	.	.	*))	-	-	-	-	-

wsj_2382	0	0	Bolar	NNP	(TOP(S(S(NP(NP*)	-	-	-	-	(1
wsj_2382	0	1	,	,	*	-	-	-	-	-
wsj_2382	0	2	the	DT	(NP(NP*	-	-	-	-	-
wsj_2382	0	3	subject	NN	*)	subject	-	1	-	-
wsj_2382	0	4	of	IN	(PP*	-	-	-	-	-
wsj_2382	0	5	a	DT	(NP(NP*	-	-	-	-	-
wsj_2382	0	6	criminal	JJ	*	-	-	-	-	-
wsj_2382	0	7	investigation	NN	*)	investigation	-	1	-	-
wsj_2382	0	8	by	IN	(PP*	-	-	-	-	-
wsj_2382	0	9	the	DT	(NP(NP*	-	-	-	-	(3
wsj_2382	0	10	FDA	NNP	*)	-	-	-	-	3)
wsj_2382	0	11	and	CC	*	-	-	-	-	-
wsj_2382	0	12	the	DT	(NP(NP(NP*	-	-	-	-	-
wsj_2382	0	13	Inspector	NNP	*	-	-	-	-	-
wsj_2382	0	14	General	NNP	*	-	-	-	-	-
wsj_2382	0	15	's	POS	*)	-	-	-	-	-
wsj_2382	0	16	office	NN	*)	office	-	5	-	-
wsj_2382	0	17	of	IN	(PP*	-	-	-	-	-
wsj_2382	0	18	the	DT	(NP*	-	-	-	-	-
wsj_2382	0	19	Health	NNP	(NML(NML*)	-	-	-	-	-
wsj_2382	0	20	and	CC	*	-	-	-	-	-
wsj_2382	0	21	Human	NNP	(NML*	-	-	-	-	-
wsj_2382	0	22	Services	NNP	*))	-	-	-	-	-
wsj_2382	0	23	Department	NNP	*))))))))	-	-	-	-	-
wsj_2382	0	24	,	,	*)	-	-	-	-	1)
wsj_2382	0	25	only	RB	(ADVP*)	-	-	-	-	-
wsj_2382	0	26	agreed	VBD	(VP*	agree	01	3	-	-
wsj_2382	0	27	to	TO	(S(VP*	-	-	-	-	-
wsj_2382	0	28	recall	VB	(VP*	recall	01	2	-	-
wsj_2382	0	29	two	CD	(NP(NP*	-	-	-	-	(5
wsj_2382	0	30	strengths	NNS	*)	strength	-	6	-	-
wsj_2382	0	31	of	IN	(PP*	-	-	-	-	-
wsj_2382	0	32	its	PRP$	(NP(NP*	-	-	-	-	(4|(1)
wsj_2382	0	33	version	NN	*)	version	-	2	-	-
wsj_2382	0	34	of	IN	(PP*	-	-	-	-	-
wsj_2382	0	35	Macrodantin	NNP	(NP*)))))	-	-	-	-	(2)|5)|4)
wsj_2382	0	36	``	``	*	-	-	-	-	-
wsj_2382	0	37	as	RB	(ADVP(ADVP*	-	-	-	-	-
wsj_2382	0	38	far	RB	*	-	-	-	-	-
wsj_2382	0	39	down	RB	*)	-	-	-	-	-
wsj_2382	0	40	as	IN	(PP*	-	-	-	-	-
wsj_2382	0	41	direct	JJ	(NP(NP*	-	-	-	-	-
wsj_2382	0	42	customers	NNS	*)	-	-	-	-	-
wsj_2382	0	43	,	,	*	-	-	-	-	-
wsj_2382	0	44	mostly	RB	*	-	-	-	-	-
wsj_2382	0	45	wholesalers	NNS	(NP*)))))))))	-	-	-	-	-
wsj_2382	0	46	,	,	*	-	-	-	-	-
wsj_2382	0	47	''	''	*	-	-	-	-	-
wsj_2382	0	48	Mr.	NNP	(NP*	-	-	-	-	(6
wsj_2382	0	49	Nesbit	NNP	*)	-	-	-	-	6)
wsj_2382	0	50	said	VBD	(VP*)	say	01	1	-	-
wsj_2382	0	51	.	.	*))	-	-	-	-	-

wsj_2382	0	0	Bolar	NNP	(TOP(S(NP(NP*)	-	-	-	-	(1
wsj_2382	0	1	,	,	*	-	-	-	-	-
wsj_2382	0	2	of	IN	(PP*	-	-	-	-	-
wsj_2382	0	3	Copiague	NNP	(NP(NP*)	-	-	-	-	-
wsj_2382	0	4	,	,	*	-	-	-	-	-
wsj_2382	0	5	N.Y.	NNP	(NP*)	-	-	-	-	-
wsj_2382	0	6	,	,	*)))	-	-	-	-	1)
wsj_2382	0	7	earlier	RBR	(ADVP*)	-	-	-	-	-
wsj_2382	0	8	began	VBD	(VP*	begin	01	2	-	-
wsj_2382	0	9	a	DT	(NP(NP*	-	-	-	-	-
wsj_2382	0	10	voluntary	JJ	*	-	-	-	-	-
wsj_2382	0	11	recall	NN	*)	recall	01	1	-	-
wsj_2382	0	12	of	IN	(PP*	-	-	-	-	-
wsj_2382	0	13	both	DT	(NP(NP*	-	-	-	-	(5
wsj_2382	0	14	its	PRP$	*	-	-	-	-	(1)
wsj_2382	0	15	100	CD	(NML(NML*	-	-	-	-	-
wsj_2382	0	16	milligram	NN	*)	-	-	-	-	-
wsj_2382	0	17	and	CC	*	-	-	-	-	-
wsj_2382	0	18	50	CD	(NML*	-	-	-	-	-
wsj_2382	0	19	milligram	NN	*))	-	-	-	-	-
wsj_2382	0	20	versions	NNS	*)	version	-	2	-	-
wsj_2382	0	21	of	IN	(PP*	-	-	-	-	-
wsj_2382	0	22	the	DT	(NP*	-	-	-	-	(2
wsj_2382	0	23	drug	NN	*))))))	drug	-	1	-	5)|2)
wsj_2382	0	24	.	.	*))	-	-	-	-	-

wsj_2382	0	0	The	DT	(TOP(S(NP*	-	-	-	-	(3
wsj_2382	0	1	FDA	NNP	*)	-	-	-	-	3)
wsj_2382	0	2	has	VBZ	(VP*	-	-	-	-	-
wsj_2382	0	3	said	VBD	(VP*	say	01	1	-	-
wsj_2382	0	4	it	PRP	(SBAR(S(NP*)	-	-	-	-	(3)
wsj_2382	0	5	presented	VBD	(VP*	present	01	2	-	-
wsj_2382	0	6	evidence	NN	(NP(NP*)	evidence	-	1	-	-
wsj_2382	0	7	it	PRP	(SBAR(S(NP*)	-	-	-	-	(3)
wsj_2382	0	8	uncovered	VBD	(VP*))))	uncover	01	1	-	-
wsj_2382	0	9	to	IN	(PP*	-	-	-	-	-
wsj_2382	0	10	the	DT	(NP*	-	-	-	-	(1
wsj_2382	0	11	company	NN	*))	company	-	1	-	1)
wsj_2382	0	12	indicating	VBG	(VP*	indicate	01	1	-	-
wsj_2382	0	13	that	IN	(SBAR*	-	-	-	-	-
wsj_2382	0	14	Bolar	NNP	(S(NP*)	-	-	-	-	(1)
wsj_2382	0	15	substituted	VBD	(VP*	substitute	01	1	-	-
wsj_2382	0	16	the	DT	(NP*	-	-	-	-	(2
wsj_2382	0	17	brand	NN	(NML*	-	-	-	-	-
wsj_2382	0	18	-	HYPH	*	-	-	-	-	-
wsj_2382	0	19	name	NN	*)	-	-	-	-	-
wsj_2382	0	20	product	NN	*)	product	-	1	-	2)
wsj_2382	0	21	for	IN	(PP*	-	-	-	-	-
wsj_2382	0	22	its	PRP$	(NP*	-	-	-	-	(4|(1)
wsj_2382	0	23	own	JJ	*))	-	-	-	-	4)
wsj_2382	0	24	to	TO	(S(VP*	-	-	-	-	-
wsj_2382	0	25	gain	VB	(VP*	gain	02	1	-	-
wsj_2382	0	26	government	NN	(NP*	-	-	-	-	-
wsj_2382	0	27	approval	NN	*	-	-	-	-	-
wsj_2382	0	28	to	TO	(S(VP*	-	-	-	-	-
wsj_2382	0	29	sell	VB	(VP*	sell	01	1	-	-
wsj_2382	0	30	generic	JJ	(NP(NP*	-	-	-	-	-
wsj_2382	0	31	versions	NNS	*)	version	-	2	-	-
wsj_2382	0	32	of	IN	(PP*	-	-	-	-	-
wsj_2382	0	33	Macrodantin	NNP	(NP*)))))))))))))))))))	-	-	-	-	(2)
wsj_2382	0	34	.	.	*))	-	-	-	-	-

wsj_2382	0	0	Bolar	NNP	(TOP(S(NP*)	-	-	-	-	(1)
wsj_2382	0	1	has	VBZ	(VP*	-	-	-	-	-
wsj_2382	0	2	denied	VBN	(VP*	deny	01	1	-	-
wsj_2382	0	3	that	IN	(SBAR*	-	-	-	-	-
wsj_2382	0	4	it	PRP	(S(NP*)	-	-	-	-	(1)
wsj_2382	0	5	switched	VBD	(VP*	switch	01	2	-	-
wsj_2382	0	6	the	DT	(NP*	-	-	-	-	(2
wsj_2382	0	7	brand	NN	(NML*	-	-	-	-	-
wsj_2382	0	8	-	HYPH	*	-	-	-	-	-
wsj_2382	0	9	name	NN	*)	-	-	-	-	-
wsj_2382	0	10	product	NN	*)	product	-	1	-	2)
wsj_2382	0	11	for	IN	(PP*	-	-	-	-	-
wsj_2382	0	12	its	PRP$	(NP*	-	-	-	-	(4|(1)
wsj_2382	0	13	own	JJ	*))	-	-	-	-	4)
wsj_2382	0	14	in	IN	(PP*	-	-	-	-	-
wsj_2382	0	15	such	JJ	(NP*	-	-	-	-	(7
wsj_2382	0	16	testing	NN	*)))))))	test	-	1	-	7)
wsj_2382	0	17	.	.	*))	-	-	-	-	-

#end document
